Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals

• DOI: 10.1111/imj.15719
• Publication Date: 2022-02-22T06:13:09Z
• Authors: Angela Pearce; Bronwyn Terrill; Jan‐Willem Alffenaar; Asad E. Patanwala; Sarah Kummerfeld; Richard Day; Mary‐Anne Young; Sophie L. Stocker
• Keywords: Pharmacogenomics; Reimbursement

Despite healthcare professionals (HCP) endorsing the clinical utility of pharmacogenomics testing, use in practice is limited.To assess HCP' perceptions pharmacogenomic testing and identify barriers to implementation.HCP involved prescribing decisions at three hospitals Sydney, Australia, were invited participate. The online survey assessed including: (i) demographic variables; (ii) use, knowledge confidence; (iii) perceived benefits; (iv) implementation; (v) operational and/or system changes personnel required implement on site.HCP predominantly medical practitioners (75/107) pharmacists (25/107). HCP was beneficial reasons for drug intolerance (85/95) risk side-effects (86/95). Although considered relevant their (79/100), few (23/100) reported past or intended future (26/100). Few confidence ability indications (14/107), order tests (19/106) communicate results with patients (16/107). Lack guidelines (62/79) (54/77) identified as major implementation pharmacogenomics. Comprehensive reimbursement guidelines, alongside models-of-care involving multidisciplinary teams local champions suggested strategies facilitate into practice.Pharmacogenomic important guide selection dosing decisions. However, limited knowledge, low an absence impede testing. Establishment resources including